Amgen's Q2 2017 earnings call highlights continued strong performance driven by volume growth for newer products like Prolia, Repatha, and KYPROLIS.  Management expresses confidence in the company's strategy and pipeline, particularly in cardiovascular and oncology.  Positive guidance updates and ongoing efforts to improve patient access for Repatha suggest a positive short-term outlook for the stock price.
[1]
